Regencell Bioscience Holdings (RGC) Total Debt (2020 - 2021)
Regencell Bioscience Holdings' (RGC) quarterly Total Debt came in at $431969.0 in Q2 2021, down 85.93% YoY from $3.1 million in Q2 2020, and down 85.93% on a QoQ basis from $3.1 million in Q2 2020.
Regencell Bioscience Holdings (RGC) Total Debt (2020 - 2021) Analysis & Trends
Regencell Bioscience Holdings (RGC) has 2 years of Total Debt data on file, last reported at $431969.0 in Q2 2021.
- Quarterly Total Debt fell 85.93% year-over-year to $431969.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $431969.0 (down 85.93% YoY) and the FY2021 annual result came in at $431969.0, down 85.93% from the prior year.
- Total Debt slipped to $431969.0 in Q2 2021, from $3.1 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $3.1 million in Q2 2020 to a low of $431969.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -5.81 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.59 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 31.47 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 13.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.92 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 760.00 Mn |
| 10 | Regencell Bioscience Holdings | 2.67 Bn | 2.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 431,969.00 |
| Jun 30, 2020 | 3.07 Mn |